+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targazyme Inc - logo

Targazyme is a clinical-stage biopharmaceutical company developing and commercializing breakthrough products to improve clinical efficacy outcomes for immunotherapies for cancer and autoimmune diseases, stem cell transplants, gene therapy and regenerative medicine. Targazyme's products are off-the-shelf enzyme/substrate kits that are used to treat cells at the point-of-care, immediately before they are infused in the patient. The company was founded in 2005 and is based in Floresville, Texas with additional offices in San Diego, California; and Basel, Switzerland.

CAR T-cell Therapy - Pipeline Insight, 2022 - Product Thumbnail Image

CAR T-cell Therapy - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 60 Pages
  • Global
From
Bone Marrow Transplant Rejection - Pipeline Review, H2 2020 - Product Thumbnail Image

Bone Marrow Transplant Rejection - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 797 Pages
  • Global
From
From
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020 - Product Thumbnail Image

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 770 Pages
  • Global
From
Genome Editing Services Market: Focus on CRISPR, 2019-2030 - Product Thumbnail Image

Genome Editing Services Market: Focus on CRISPR, 2019-2030

  • Report
  • November 2019
  • 290 Pages
  • Global
From
From
From
From
From
CAR T - Pipeline Insight, 2022 - Product Thumbnail Image

CAR T - Pipeline Insight, 2022

  • Clinical Trials
  • February 2022
  • 665 Pages
  • Global
From
Loading Indicator